) Since its origin in Fall 1996, the Pharmacology Core has steadily grown into being an important CCC resource for several investigators. Its mission is providing expertise in pharmacological sciences, including kinetics, dynamics, biopharmaceutics and physical pharmacy. Pharmacokinetic support includes drug absorption, metabolism, distribution, elimination, bioactivation and drug-drug interactions. Pharmacodynamic support includes molecular effects of drug exposure, and in vitro toxicity testing. Biopharmaceutic support includes the influence of dose and dosage form on pharmacokinetics. Physical pharmacy support includes production of (approximate dose) prototype forms of drugs for preclinical studies and clinical forms for IND studies. Enhancements of research by the Core take the form of study design, data acquisition, data analysis, and interpretation of results, including technical writing for manuscripts and grant proposals written by CCC investigators. This core also developed and oversees the Quality Assurance Plan for tracking and handling clinical pharmacology specimens throughout the Institute. Key features of this Core are the scope of services provided, its integral role in clinical specimen handling, existing collegial relationships, direct consultation for requesting investigators, and the interests and commitment of its staff. Pharmacological contributions benefited 5 Programs, including Developmental Therapeutics, Breast Cancer, Molecular Biology and Genetics, Prostate Cancer and Protease Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-22S1
Application #
6503921
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-09-27
Project End
2001-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26
Bonomi, Robin; Popov, Vadim; Laws, Maxwell T et al. (2018) Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [18F]-2-Fluorobenzoylaminohexanoicanilide. J Med Chem 61:7116-7130
Paximadis, Peter; Beebe-Dimmer, Jennifer L; George, Julie et al. (2018) Comparing Treatment Strategies for Stage I Small-cell lung Cancer. Clin Lung Cancer 19:e559-e565
Modi, Dipenkumar; Al-Kadhimi, Zaid; Chen, Wei et al. (2018) A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation. Am J Hematol 93:E96-E98
Patki, Mugdha; McFall, Thomas; Rosati, Rayna et al. (2018) Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. Sci Rep 8:16006
Teslow, Emily A; Bao, Bin; Dyson, Greg et al. (2018) Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol 12:1138-1152
Rathinam, Rajamani; Rosati, Rita; Jamesdaniel, Samson (2018) CRISPR/Cas9-mediated knockout of Lim-domain only four retards organ of Corti cell growth. J Cell Biochem 119:3545-3553
Munkanatta Godage, Dhanushka N P; VanHecke, Garrett C; Samarasinghe, Kusal T G et al. (2018) SMYD2 glutathionylation contributes to degradation of sarcomeric proteins. Nat Commun 9:4341
Han, Jing; Li, Yue; Liu, Xiuli et al. (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS One 13:e0193031
McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K et al. (2018) Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep 8:9043

Showing the most recent 10 out of 826 publications